Klebsiella pneumoniae infections Pipeline

DelveInsight’s, “Klebsiella pneumoniae infections - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Klebsiella pneumoniae infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Klebsiella pneumoniae infections: Understanding

Klebsiella pneumoniae infections: Overview

Klebsiella pneumoniae infections are caused by a Gram-negative, encapsulated bacterium that can lead to a wide range of serious diseases, particularly in hospital settings but increasingly in the community due to the emergence of hypervirulent strains. These infections occur when the bacterium, which typically colonizes the gastrointestinal and respiratory tracts, breaches mucosal barriers and invades sterile body sites. The main causes include colonization of the gut or oropharynx followed by spread, especially in patients with risk factors such as hospitalization, ICU admission, invasive medical devices, prior antibiotic use, diabetes, immunosuppression, and chronic illness. Transmission usually happens through direct contact with contaminated surfaces or medical equipment, not through airborne spread.

There are two major types of K. pneumoniae strains: classical strains (cKp), responsible for hospital-acquired infections in vulnerable patients, and hypervirulent strains (hvKp), which can cause severe, invasive disease even in healthy individuals. Symptoms vary based on the site of infection, pneumonia may present with fever, cough, and bloody sputum, while UTIs can cause painful urination and flank pain. Sepsis can develop rapidly from bloodstream infections, with fever, confusion, and low blood pressure. Other manifestations include liver abscesses, meningitis, skin infections, and in rare cases, endophthalmitis leading to vision loss.

The diagnosis of Klebsiella pneumoniae infections has evolved from traditional culture-based methods to more rapid and sensitive molecular techniques. Conventional approaches such as microscopic examination, culturing of sputum, blood, urine, or wound samples, and biochemical testing remain standard but are time-consuming and require skilled laboratory infrastructure. Molecular diagnostics, including nucleic acid amplification tests, have significantly improved detection speed and accuracy. Techniques like Loop-mediated Isothermal Amplification (LAMP) and Closed Dumbbell-mediated Isothermal Amplification (CDA) target conserved genes like rcsA and offer rapid, sensitive, and specific results, often within an hour. CDA, in particular, has shown superior specificity and simplicity over LAMP, making it ideal for use in primary care and field settings. Real-time PCR and droplet digital PCR (ddPCR) are valuable for detecting and quantifying K. pneumoniae directly from complex samples such as blood and feces. Recombinase Polymerase Amplification (RPA) and MALDI-TOF MS are also being increasingly adopted for rapid post-culture identification. Accurate diagnosis relies on appropriate sample types, including sputum, blood, urine, and abscess material, depending on the infection site.

Treatment of Klebsiella pneumoniae infections, particularly those caused by multidrug-resistant (MDR) or carbapenem-resistant strains, requires careful antibiotic selection guided by susceptibility testing. For ESBL-producing strains, carbapenems such as meropenem or imipenem are typically the first-line therapy, with high-dose, prolonged infusions improving drug efficacy in severe cases. Infections caused by carbapenem-resistant strains often require combination therapy using agents like colistin, tigecycline, fosfomycin, or aminoglycosides, though each has limitations regarding site penetration or toxicity. Tigecycline may be used in combination or at high doses for certain severe infections, but is generally avoided in UTIs and bacteremia. Newer beta-lactam/beta-lactamase inhibitor combinations are emerging but are not yet widely adopted.

 

"Klebsiella pneumoniae infections- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella pneumoniae infections pipeline landscape is provided which includes the disease overview and Klebsiella pneumoniae infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella pneumoniae infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella pneumoniae infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Klebsiella pneumoniae infections R&D. The therapies under development are focused on novel approaches to treat/improve Klebsiella pneumoniae infections.

 

Klebsiella pneumoniae infections Emerging Drugs Chapters

This segment of the Klebsiella pneumoniae infections report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Klebsiella pneumoniae infections Emerging Drugs

• CHO V08: CHO Pharma

CHO-V08 is currently being developed by CHO Pharma as a prevention vaccine against nosocomial and community-acquired infection caused by hypervirulent Klebsiella pneumoniae K1 and K2 serotypes. The bivalent vaccine that targets two major pathogenic serotypes K1 and K2 is being developed using the advanced carbohydrate-based vaccine technology. Preclinical studies have proven that CHO-V08 vaccine can induce potent antibody response against the hypervirulent KP strains.  Currently, CHO V08 is being evaluated in Phase I stage of its clinical trial.

Further product details are provided in the report……..

 

Klebsiella pneumoniae infections: Therapeutic Assessment

This segment of the report provides insights about the different Klebsiella pneumoniae infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Klebsiella pneumoniae infections
• There are approx. 8+ key companies which are developing the therapies for Klebsiella pneumoniae infections. The companies which have their Klebsiella pneumoniae infections drug candidates in the most advanced stage, i.e. Phase I include, CHO Pharma.

 

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Klebsiella pneumoniae infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Klebsiella pneumoniae infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Klebsiella pneumoniae infections therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella pneumoniae infections drugs.

 

Klebsiella pneumoniae infections Report Insights

• Klebsiella pneumoniae infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Klebsiella pneumoniae infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Klebsiella pneumoniae infections drugs?
• How many Klebsiella pneumoniae infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Klebsiella pneumoniae infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Klebsiella pneumoniae infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Klebsiella pneumoniae infections and their status?
• What are the key designations that have been granted to the emerging drugs?